XML 29 R16.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Stock-Based Compensation | 3 Months Ended
--- | ---
Mar. 31, 2018
Stock-Based Compensation |
Stock-Based Compensation | Note 9—Stock-Based Compensation For the three months ended March 31, 2018 and 2017, the Company’s income before income taxes was reduced for stock-based compensation expense of $12.7 and $12.1, respectively. In addition, for the three months ended March 31, 2018 and 2017, the Company recognized aggregate income tax benefits associated with stock-based compensation of $5.9 and $11.0, respectively, in the provision for income taxes in the accompanying Condensed Consolidated Statements of Income, which include the excess tax benefits from option exercises of $4.1 (or $0.01 per share) and $8.0 (or $0.02 per share), respectively. T he impact associated with recognizing excess tax benefits from option exercises in the provision for income taxes on our consolidated financial statements could result in significant fluctuations in our effective tax rate in the future, since the provision for income taxes will be impacted by the timing and intrinsic value of future stock-based compensation award exercises. Stock-based compensation expense includes the estimated effects of forfeitures, which are adjusted over the requisite service period to the extent actual forfeitures differ or are expected to differ from such estimates. Changes in estimated forfeitures are recognized in the period of change and impact the amount of expense to be recognized in future periods. The expense incurred for stock-based compensation plans is included in Selling, general and administrative expenses in the accompanying Condensed Consolidated Statements of Income. Stock Options In May 2017, the Company adopted the 2017 Stock Purchase and Option Plan for Key Employees of Amphenol and Subsidiaries (the “2017 Employee Option Plan”). The Company also continues to maintain the 2009 Stock Purchase and Option Plan for Key Employees of Amphenol and Subsidiaries, as amended (the “2009 Employee Option Plan”) and the 2000 Stock Purchase and Option Plan for Key Employees of Amphenol and Subsidiaries, as amended (the “2000 Employee Option Plan”). No additional stock options will be granted under the 2009 Employee Option Plan. The 2000 Employee Option Plan expired in May 2011, except that its terms continue with respect to outstanding options granted thereunder. A committee of the Company’s Board of Directors has been authorized to grant stock options pursuant to the 2017 Employee Option Plan. The number of shares of the Company’s Class A Common Stock (“Common Stock”) reserved for issuance under the 2017 Employee Option Plan is 30,000,000 shares. As of March 31, 2018, there were 23,016,700 shares of Common Stock available for the granting of additional stock options under the 2017 Employee Option Plan. Options granted under the 2017 Employee Option Plan and the 2009 Employee Option Plan generally vest ratably over a period of five years from the date of grant and are generally exercisable over a period of ten years from the date of grant. Options granted under the 2000 Employee Option Plan are fully vested and are generally exercisable over a period of ten years from the date of grant. In 2004, the Company adopted the 2004 Stock Option Plan for Directors of Amphenol Corporation (the “2004 Directors Option Plan”). The 2004 Directors Option Plan is administered by the Company’s Board of Directors. The 2004 Directors Option Plan expired in May 2014, except that its terms continue with respect to outstanding options granted thereunder. Options were last granted under the 2004 Directors Option Plan in May 2011. Options granted under the 2004 Directors Option Plan are fully vested and are generally exercisable over a period of ten years from the date of grant. Stock option activity for the three months ended March 31, 2018 was as follows:
|  |  |  |  |  |  | Weighted |  |  |  |
|  |  |  |  |  | Average |  | Aggregate |
|  |  |  | Weighted |  | Remaining |  | Intrinsic |
|  |  |  | Average |  | Contractual |  | Value |
|  | Options |  | Exercise Price |  | Term (in years) |  | (in millions) |
Options outstanding at January 1, 2018 |  | 33,222,364 |  | $ | 52.27 |  | 7.05 |  | $ | 1,180.3 |
Options granted |  | — |  |  |  |  |  |  |  |  |
Options exercised |  | (602,549) |  |  |  |  |  |  |  |  |
Options forfeited |  | (32,240) |  |  |  |  |  |  |  |  |
Options outstanding at March 31, 2018 |  | 32,587,575 |  | $ | 52.58 |  | 6.84 |  | $ | 1,093.2 |
Vested and non-vested options expected to vest at March 31, 2018 |  | 30,726,902 |  | $ | 51.92 |  | 6.76 |  | $ | 1,051.0 |
Exercisable options at March 31, 2018 |  | 13,086,775 |  | $ | 39.76 |  | 5.20 |  | $ | 606.8 |
A summary of the status of the Company’s non-vested options as of March 31, 2018 and changes during the three months then ended is as follows:
|  |  |  | Weighted |
|  |  |  | Average |
|  |  |  | Fair Value at |
|  | Options |  | Grant Date |
Non-vested options at January 1, 2018 |  | 19,600,440 |  | $ | 8.29 |
Options granted |  | — |  |  | — |
Options vested |  | (67,400) |  |  | 8.13 |
Options forfeited |  | (32,240) |  |  | 8.56 |
Non-vested options at March 31, 2018 |  | 19,500,800 |  | $ | 8.29 |
During the three months ended March 31, 2018 and 2017, the following activity occurred under the Company’s option plans:
|  | Three Months Ended |
|  | March 31, |
|  | 2018 |  | 2017 |
Total intrinsic value of stock options exercised |  | $ | 34.3 |  | $ | 34.5 |
Total fair value of stock options vested |  |  | 0.5 |  |  | 0.7 |
As of March 31, 2018, the total compensation cost related to non-vested options not yet recognized was approximately $108.5 with a weighted average expected amortization period of 3.14 years. The grant-date fair value of each option grant under the 2000 Employee Option Plan, the 2009 Employee Option Plan, the 2017 Employee Option Plan and the 2004 Directors Option Plan is estimated using the Black-Scholes option pricing model. The grant-date fair value of each share grant is determined based on the closing share price of the Company’s Common Stock on the date of the grant. The fair value is then amortized on a straight-line basis over the requisite service period of the awards, which is generally the vesting period. Use of a valuation model for option grants requires management to make certain assumptions with respect to selected model inputs. Expected share price volatility is calculated based on the historical volatility of the Common Stock and implied volatility derived from related exchange traded options. The average expected life is based on the contractual term of the option and expected exercise and historical post-vesting termination experience. The risk-free interest rate is based on U.S. Treasury zero-coupon issuances with a remaining term equal to the expected life assumed at the date of grant. The expected annual dividend per share is based on the Company’s dividend rate. Restricted Shares In 2012, the Company adopted the 2012 Restricted Stock Plan for Directors of Amphenol Corporation (the “2012 Directors Restricted Stock Plan”). The 2012 Directors Restricted Stock Plan is administered by the Company’s Board of Directors. As of March 31, 2018, the number of restricted shares available for grant under the 2012 Directors Restricted Stock Plan was 124,164. Restricted shares granted under the 2012 Directors Restricted Stock Plan generally vest on the first anniversary of the grant date. Grants under the 2012 Directors Restricted Stock Plan entitle the holder to receive shares of the Company’s Common Stock without payment. Restricted share activity for the three months ended March 31, 2018 was as follows:
|  |  |  |  |  |  | Weighted Average |
|  |  |  |  |  | Remaining |
|  | Restricted |  | Fair Value at |  | Amortization |
|  | Shares |  | Grant Date |  | Term (in years) |
Restricted shares outstanding at January 1, 2018 |  | 12,905 |  | $ | 73.25 |  | 0.37 |
Restricted shares granted |  | — |  |  | — |  |  |
Restricted shares outstanding at March 31, 2018 |  | 12,905 |  | $ | 73.25 |  | 0.13 |
As of March 31, 2018, the total compensation cost related to non-vested restricted shares not yet recognized was approximately $0.1 with a weighted average expected amortization period of 0.13 years.

X
- Definition The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -URI http://asc.fasb.org/subtopic&trid=2208855 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration